Clarity Medical Group Holding Limited: Poll Results and Key Takeaways from Extraordinary General Meeting

Date: 27 February 2026

Stock Code: 1406 (Hong Kong Stock Exchange)

Overview

Clarity Medical Group Holding Limited (“the Company”) convened an Extraordinary General Meeting (EGM) on 27 February 2026, where significant resolutions were passed with overwhelming shareholder support. The poll results and related details may have implications for shareholders and could potentially impact the share value, given the ongoing litigation and board changes.

Key Resolutions Passed at the EGM

1. Re-election of Directors
   • Mr. Sun Peng was re-elected as a non-executive Director of the Company, following his appointment by the Board. The Board was also authorised to fix his remuneration.
   • Mr. Xu Anliang was re-elected as an independent non-executive Director, with the Board similarly authorised to set his remuneration.
   • Voting Outcome: Both resolutions were unanimously approved, with 281,105,368 votes (100%) in favour, and none against.
2. Shareholder Mandate on Litigation and Corporate Governance
   • Shareholders authorised the Board to communicate to the Court of First Instance of the High Court of Hong Kong (the “Court”) regarding the HCMP 1627 Action, originating from a summons issued by TSE Wai Ip against the Company.
   • The mandate supports:
     • The Company’s continued efforts in pursuing its resumption application to the Exchange.
     • The current Board’s handling of allegations (including those raised by the Plaintiff) through established internal corporate governance processes, especially via the Special Committee’s ongoing independent investigations.
     • Explicit non-endorsement of the legal action initiated by the Plaintiff (TSE Wai Ip) and support for the Board in defending the HCMP 1627 Action.
   • Voting Outcome: The resolution was also unanimously passed, with 281,105,368 votes (100%) for and none against.

Shareholder and Market-Sensitive Information

• Litigation Update: The Company is currently defending itself in a legal action (HCMP 1627 of 2025) brought by a shareholder, TSE Wai Ip. The litigation relates to allegations against the Company, and shareholder approval now reinforces the Board’s mandate to address these through internal governance and to continue defending the case.
• Corporate Governance: The ongoing independent investigation by a Special Committee into the allegations signals a commitment to transparency and governance standards. Shareholders have explicitly supported the Special Committee’s process, which could impact investor confidence.
• Board Composition: The EGM saw the re-election of key directors, ensuring continuity amid the ongoing legal and operational challenges. However, several directors, including Mr. Sun Peng and Mr. Xu Anliang, were absent from the EGM due to other engagements.
• Voting Rights and Participation: Out of 536,334,496 shares entitled to attend and vote, 281,105,368 shares were represented and voted, and there was no abstention or opposition. There were no shareholders required to abstain under the Hong Kong Listing Rules, nor any intention stated in advance to vote against or abstain.

Potential Share Price Impact

The confirmation of overwhelming shareholder support for the current Board and its approach to ongoing litigation and governance matters may be seen as a positive sign for stability and continuity within Clarity Medical Group. However, the existence of active litigation (HCMP 1627 Action) and the need for ongoing independent investigation are factors investors should monitor closely, as developments in the case could have material implications for the Company’s reputation and share price.

Board Composition as of Announcement Date

• Executive Director: Mr. JIANG Bo (also CEO and EGM Chairman)
• Non-Executive Directors: Mr. CHEN Jiarong, Professor WANG Qinmei, Mr. SUN Peng
• Independent Non-Executive Directors: Mr. WANG Can, Ms. CI Ying, Dr. CHEN Poujian, Mr. XU Anliang

Other Procedural Details

• EGM poll was scrutinised by Tricor Investor Services Limited, the Company’s branch share registrar and transfer office in Hong Kong.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or an offer to buy or sell any securities. Investors should conduct their own research and consult professional advisors before making any investment decisions. The information herein is based on the Company’s public disclosures as of 27 February 2026 and is subject to change without notice.

View CLARITY MEDICAL Historical chart here